Nasometin (Mometasone Furoate)

Mometasone furoate acts as an agonist at glucocorticoid receptors in the nasal mucosa. By binding these receptors, it alters gene expression to suppress inflammatory cytokines and mediators, reducing swelling and mucus production in the nasal passages.

The specific dosing regimen for Nasometin is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Nasometin to pregnant or nursing individuals.

To request Nasometin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasometin (mometasone furoate) offers high topical potency with minimal systemic absorption, similar to other intranasal corticosteroids such as fluticasone propionate. Choice between products often depends on physician preference, patient response, device comfort and local regulatory approvals.

Store Nasometin at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Nasometin is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, cataract formation or other vision changes, and suppression of the hypothalamic‑pituitary‑adrenal axis, which could affect the body’s stress response. Any unusual symptoms should be reported to a healthcare professional promptly.

Nasometin should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, and in patients with active untreated nasal or sinus infections unless directed by a clinician. Caution is also advised for patients with uncontrolled glaucoma or cataracts.